Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma

Haematologica

Volumn 99, Issue 4, 2014, Pages 726-735

  Aukema, Sietse M ^a,b   Kreuz, Markus ^c   Kohler, Christian W ^d   Rosolowski, Maciej ^c   Hasenclever, Dirk ^c   Hummel, Michael ^e   Küppers, Ralf ^f   Lenze, Dido ^e   Ott, German ^g   Pott, Christiane ^a   Richter, Julia ^a   Rosenwald, Andreas ^h   Szczepanowski, Monika ^a   Schwaenen, Carsten ⁱ   Stein, Harald ^e   Trautmann, Heiko ^a   Wessendorf, Swen ⁱ   Trümper, Lorenz ^j   Loeffler, Markus ^c   Spang, Rainer ^d   Kluin, Philip M ^b   Klapper, Wolfram ^g   Siebert, Reiner ^a   more..

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d UNIVERSITY OF REGENSBURG   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f UNIVERSITY OF DUISBURG ESSEN   (Germany)

^g ROBERT BOSCH HOSPITAL   (Germany)

^h UNIVERSITY OF WÜRZBURG   (Germany)

ⁱ UNIVERSITY HOSPITAL ULM   (Germany)

^j UNIVERSITY OF GÖTTINGEN   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; PROTEIN BCL 6; IMMUNOGLOBULIN HEAVY CHAIN; ONCOPROTEIN; PROTEIN BCL 2; TRANSCRIPTOME;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; BIOINFORMATICS; BURKITT LYMPHOMA; COPY NUMBER VARIATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; GENE TRANSLOCATION; HUMAN; IMMUNOGLOBULIN GENE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; MUTATIONAL ANALYSIS; ONCOGENE MYC; OVERALL SURVIVAL; PROTO ONCOGENE; CANCER GRADING; CLUSTER ANALYSIS; GENE EXPRESSION REGULATION; GENETICS; GENOMICS; LYMPHOMA, B-CELL; METABOLISM; MIDDLE AGED; MORTALITY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BURKITT LYMPHOMA; CLUSTER ANALYSIS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MYC; GENOMICS; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; NEOPLASM GRADING; ONCOGENE PROTEINS, FUSION; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-BCL-6; TRANSCRIPTOME; TRANSLOCATION, GENETIC;

EID: 84897394082     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.091827     Document Type: Article

References (55)

1. Kluin P, Schuuring E. Molecular cytogenetics of lymphoma: where do we stand in 2010? Histopathology. 2011;58(1):128-44.
2. Siebert R. Mature B-and T-cell neoplasms and Hodgkin lymphomas. In: Heim S, Mitelman F, editors. Cancer Cytogenetics. 3rd ed. Hoboken, New Jersey: John Wiley & Sons, Inc.; 2009. p. 297-374.
3. Hummel M, Bentink S, Berger H, Klapper W, Wessendorf S, Barth TF, et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med. 2006;354(23):2419-30.
4. Kluin P, Harris N, Stein H, Leoncini L, Raphaël M, Campo E, et al. B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. In: Swerdlow, Campo, Harris, Jaffe, Pileri, Stein, et al, editors. WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues. 4th ed. Lyon: IARC; 2008. p. 265-6.
5. Lin P, Dickason TJ, Fayad LE, Lennon PA, Hu P, Garcia M, et al. Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. Cancer. 2012;118(6):1566-73.
6. Boerma EG, Siebert R, Kluin PM, Baudis M. Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytogenetics in the light of today's knowledge. Leukemia. 2009;23(2):225-34.
7. Salaverria I, Zettl A, Bea S, Hartmann EM, Dave SS, Wright GW, et al. Chromosomal alterations detected by comparative genomic hybridization in subgroups of gene expression-defined Burkitt's lymphoma. Haematologica. 2008;93(9):1327-34.
8. Scholtysik R, Kreuz M, Klapper W, Burkhardt B, Feller AC, Hummel M, et al. Detection of genomic aberrations in molecularly defined Burkitt's lymphoma by array-based, high resolution, single nucleotide polymorphism analysis. Haematologica. 2010;95(12):2047-55.
9. Snuderl M, Kolman OK, Chen YB, Hsu JJ, Ackerman AM, Dal Cin P, et al. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol. 2010;34(3):327-40.
10. Le Gouill S, Talmant P, Touzeau C, Moreau A, Garand R, Juge-Morineau N, et al. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement. Haematologica. 2007;92(10):1335-42.
11. Li S, Lin P, Fayad LE, Lennon PA, Miranda RN, Yin CC, et al. B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome. Mod Pathol. 2012;25(1): 145-56.
12. Barrans S, Crouch S, Smith A, Turner K, Owen R, Patmore R, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol. 2010;28(20):3360-5.
13. Savage KJ, Johnson NA, Ben Neriah S, Connors JM, Sehn LH, Farinha P, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood. 2009;114(17):3533-7.
14. Cuccuini W, Briere J, Mounier N, Voelker H, Rosenwald A, Sundstrom C, et al. MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by HDT/ASCT. A bio-CORAL report. Blood. 2012;119(20):4619-24.
15. Klapper W, Stoecklein H, Zeynalova S, Ott G, Kosari F, Rosenwald A, et al. Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Leukemia. 2008;22(12):2226-9.
16. Aukema SM, Siebert R, Schuuring E, van Imhoff GW, Kluin-Nelemans HC, Boerma E, et al. Double-hit B-cell lymphomas. Blood. 2011;117(8):2319-31.
17. Horn H, Schmelter C, Leich E, Salaverria I, Katzenberger T, Ott MM, et al. Follicular lymphoma grade 3b is a distinct neoplasm according to cytogenetic and immunohistochemical profiles. Haematologica. 2011;96 (9):1327-34.
18. Bosga-Bouwer AG, van den Berg A, Haralambieva E, de Jong D, Boonstra R, Kluin P, et al. Molecular, cytogenetic, and immunophenotypic characterization of follicular lymphoma grade 3B; a separate entity or part of the spectrum of diffuse large Bcell lymphoma or follicular lymphoma? Hum Pathol. 2006;37(5):528-33.
19. Johnson NA, Slack GW, Savage KJ, Connors JM, Ben-Neriah S, Rogic S, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30(28):3452-9.
20. Valera A, López-Guillermo A, Cardesa-Salzmann T, Climent F, González-Barca E, Mercadal S, et al. MYC protein expression and genetic alterations have prognostic impact in diffuse large B-cell lymphoma treated with immunochemotherapy. Haematologica. 2013;98(10):1554-62.
21. Niitsu N, Okamoto M, Miura I, Hirano M. Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations. Leukemia. 2009;23(4):777-83.
22. Dave SS, Fu K, Wright GW, Lam LT, Kluin P, Boerma EJ, et al. Molecular diagnosis of Burkitt's lymphoma. N Engl J Med. 2006;354(23):2431-42.
23. Nagel I, Akasaka T, Klapper W, Gesk S, Böttcher S, Ritgen M, et al. Identification of the gene encoding cyclin E1 (CCNE1) as a novel IGH translocation partner in t(14;19)(q32;q12) in diffuse large B-cell lymphoma. Haematologica. 2009;94(7):1020-3.
24. Martin-Subero JI, Ibbotson R, Klapper W, Michaux L, Callet-Bauchu E, Berger F, et al. A comprehensive genetic and histopathologic analysis identifies two subgroups of B-cell malignancies carrying a t(14;19)(q32;q13) or variant BCL3-translocation. Leukemia. 2007;21(7):1532-44.
25. Bertrand P, Bastard C, Maingonnat C, Jardin F, Maisonneuve C, Courel MN, et al. Mapping of MYC breakpoints in 8q24 rearrangements involving nonimmunoglobulin partners in B-cell lymphomas. Leukemia. 2007;21(3):515-23.
26. Au WY, Horsman DE, Ohno H, Klasa RJ, Gascoyne RD. Bcl-3/IgH translocation (14;19)(q32;q13) in non-Hodgkin's lymphomas. Leuk Lymphoma. 2002;43(4):813-6.
27. Salaverria I, Siebert R. The gray zone between Burkitt's lymphoma and diffuse large B-cell lymphoma from a genetics perspective. J Clin Oncol. 2011;29(14):1835-43.
28. Klapper W, Kreuz M, Kohler CW, Burkhardt B, Szczepanowski M, Salaverria I, et al. Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma. Blood. 2012;119(8):1882-7.
29. Salaverria I, Philipp C, Oschlies I, Kohler CW, Kreuz M, Szczepanowski M, et al. Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adults. Blood. 2011;118 (1):139-47.
30. Bemark M, Neuberger MS. The c-MYC allele that is translocated into the IgH locus undergoes constitutive hypermutation in a burkitt's lymphoma line. Oncogene. 2000; 19(30):3404-10.
31. Bhatia K, Spangler G, Gaidano G, Hamdy N, Dalla-Favera R, Magrath I. Mutations in the coding region of c-myc occur frequently in acquired immunodeficiency syndromeassociated lymphomas. Blood. 1994;84 (3):883-8.
32. Bentink S, Wessendorf S, Schwaenen C, Rosolowski M, Klapper W, Rosenwald A, et al. Pathway activation patterns in diffuse large B-cell lymphomas. Leukemia. 2008; 22(9):1746-54.
33. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. A gene expressionbased method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA. 2003;100(17): 9991-6.
34. Schrader A, Bentink S, Spang R, Lenze D, Hummel M, Kuo M, et al. High myc activity is an independent negative prognostic factor for diffuse large B cell lymphomas. Int J Cancer. 2012;131(4):E348-61.
35. Johnson NA, Savage KJ, Ludkovski O, Ben Neriah S, Woods R, Steidl C, et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood. 2009;114 (11):2273-9.
36. Haralambieva E, Boerma EJ, van Imhoff GW, Rosati S, Schuuring E, Muller-Hermelink HK, et al. Clinical, immunophenotypic, and genetic analysis of adult lymphomas with morphologic features of burkitt lymphoma. Am J Surg Pathol. 2005;29(8):1086-94.
37. Klapper W, Szczepanowski M, Burkhardt B, Berger H, Rosolowski M, Bentink S, et al. Molecular profiling of pediatric mature Bcell lymphoma treated in population-based prospective clinical trials. Blood. 2008;112 (4):1374-81.
38. Richter J, Schlesner M, Hoffmann S, Kreuz M, Leich E, Burkhardt B, et al. Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat Genet. 2012;44(12):1316-20.
39. Love C, Sun Z, Jima D, Li G, Zhang J, Miles R, et al. The genetic landscape of mutations in Burkitt lymphoma. Nat Genet. 2012; 44(12):1321-5.
40. Schmitz R, Young RM, Ceribelli M, Jhavar S, Xiao W, Zhang M, et al. Burkitt lym-phoma pathogenesis and therapeutic targets from structural and functional genomics. Nature. 2012;490(7418):116-20.
41. Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011;476(7360):298-303.
42. Pasqualucci L, Dominguez-Sola D, Chiarenza A, Fabbri G, Grunn A, Trifonov V, et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature. 2011;471(7337):189-95.
43. Havelange V, Ameye G, Théate I, Callet-Bauchu E, Mugneret F, Michaux L, et al. Patterns of genomic aberrations suggest that Burkitt lymphomas with complex karyotype are distinct from other aggressive B-cell lymphomas with MYC rearrangement. Genes, Chromosomes Cancer. 2013;52(1):81-92.
44. Nie Z, Hu G, Wei G, Cui K, Yamane A, Resch W, et al. C-myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell. 2012;151(1):68-79.
45. Lin CY, Loven J, Rahl PB, Paranal RM, Burge CB, Bradner JE, et al. Transcriptional amplification in tumor cells with elevated c-myc. Cell. 2012;151(1):56-67.
46. Pillai RK, Sathanoori M, Van Oss SB, Swerdlow SH. Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas. Am J Surg Pathol. 2013; 37(3):323-32.
47. Gollub W, Stassek B, Huckhagel T, Bernd H, Krokowski M, Merz H, et al. BCL6-translocations affect the phenotype of follicular lymphomas only in the absence of t(14;18)IgH/BCL2. Anticancer Res. 2009;29 (11):4649-55.
48. Green TM, Young KH, Visco C, Xu-Monette ZY, Orazi A, Go RS, et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30(28):3460-7.
49. Horn H, Ziepert M, Becher C, Barth TF, Bernd HW, Feller AC, et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood. 2013;121(12):2253-63.
50. Gupta M, Maurer MJ, Wellik LE, Law ME, Han JJ, Ozsan N, et al. Expression of myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOP. Blood. 2012;120(22):4400-6.
51. Schlegelberger B, Zwingers T, Harder L, Nowotny H, Siebert R, Vesely M, et al. Clinicopathogenetic significance of chromosomal abnormalities in patients with blastic peripheral B-cell lymphoma. Blood. 1999;94(9):3114-20.
52. Valera A, Balague O, Colomo L, Martinez A, Delabie J, Taddesse-Heath L, et al. IG/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas. Am J Surg Pathol. 2010;34(11): 1686-94.
53. Ott G, Ziepert M, Klapper W, Horn H, Szczepanowski M, Bernd H, et al. Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. Blood. 2010;116(23):4916-25.
54. Masqué-Soler N, Szczepanowski M, Kohler CW, Spang R, Klapper W. Molecular classification of mature aggressive B-cell lymphoma using digital multiplexed gene expression on formalin-fixed paraffinembedded biopsy specimens. Blood. 2013;122(11):1985-6.
55. Scheid S, Spang R. Twilight; a bioconductor package for estimating the local false discovery rate. Bioinformatics. 2005;21(12): 2921-2